Navigation Links
Product Strategies for Non-Oral Hematology Drugs
Date:3/22/2013

DUBLIN, March 22, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Product Strategies for Non-Oral Hematology Drugs" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The administration of non-oral drugs for the treatment of blood disorders has evolved over the past ten years to include heparin analogs and recombinant proteins designed to treat chronic conditions that are life threatening and often debilitating illnesses. As the availability of drugs based on new APIs or molecular entities has grown, the product strategies in the marketplace have increased in specificity and sophistication.

The chronic nature of many blood diseases and the growing trend toward patient self-administration for non-oral medications is requiring drug developers and product managers to refine their product strategy at the highest level, with formulation and device selection decisions being made prior to the clinical trial phase of development.

Key Topics Covered:

Executive Summary

Therapeutic Hematology Market Dynamics
- Evolution in Drug Therapies
- Growth of Self-Administration
- Key Markets for Hematology Drug Therapeutics
- Anemia
- Deep Vein Thrombosis
- Heart Valve Prosthesis
- Neutropenia
- Pulmonary Embolism
- Competitive Landscape
- Opportunities and Risks



Non-Oral Hematology Drug Formulation and Packaging Factors
- Extended Release Formulations
- Packaging - Vial vs Prefilled Device
- Vial Strategies
- Prefilled Device Strategies
- Prefilled Syringes
- Autoinjectors
- Pen Injectors


Non-Oral Hematology Drug Administration Factors
- Dosing
- Dose Frequency
- Route of Administration
- Intravenous
- Subcutaneous

Non-Oral Hematology Drugs - Product Analysis and Market Data

Profiles of Hematology Drug Companies

For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/qg3f6l/product

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA
3. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
4. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
5. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
6. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
7. National Stakeholders Meet To Consider Improvements In Antimicrobial Use In Food Animal Production
8. New Reproductive Support Dietary Supplement, Pregnitude™, Now Available For Women Having Difficulty Conceiving
9. China Biologic Products Reports Higher Results for the First Quarter 2012
10. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
11. Allied Healthcare Products Reports Loss on Sales Decline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... 5, 2017 The Cincinnati ... Pharmacy, Inc. (NYSE: DPLO), has been awarded a Top ... Results are based on an employee survey administered ... and workplace improvement. The survey measures several aspects of workplace ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, ... with the Fertility Center of California, is pleased to announce the addition of ... and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used ...
(Date:6/26/2017)... ... 26, 2017 , ... If the devil is in the ... these days. According to recent estimates, 75 – 80% of the medical bills ... studies point to Electronic Health Records (EHR) with automated features designed to ease ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United States Senate on Thursday ... Better Care Reconciliation Act. It differs significantly from the American Health Care Act, which ... in committee, or the House will have to take up the Senate version as-is, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, ... medications in select Florida and Texas doctors' offices and clinics. This breakthrough testing ... of genetic testing recognizes the role genes play in determining an individual's tolerance ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... announced the launch of Care Management Alerts and Dashboards, an innovative new service ... Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time data ...
Breaking Medicine News(10 mins):